Post by Bristol Myers Squibb

1,885,550 followers

At #ASCO26, new data will be presented for an investigational EGFRxHER3 bispecific antibody-drug conjugate in multiple solid tumors. We remain focused on pushing the boundaries of innovation across oncology and exploring new approaches for patients with significant unmet needs. Learn more about how we aim to advance science for people living with hard-to-treat cancers: https://bit.ly/4akmwxq #OneBMS

Post content

Video Content